Published in final edited form as:

Biochem Pharmacol. 2009 October 1; 78(7): 686–692. doi:10.1016/j.bcp.2009.05.014.

Age Dependent Nicotinic Influences over Dopamine Neuron Synaptic Plasticity

Andon N. Placzek, Tao A. Zhang, and John A. Dani

Department of Neuroscience, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas 77030

Abstract

A relatively low in vivo dose of nicotine induces long-term potentiation in midbrain dopaminergic neurons in young mice, but not in adults.

The dopamine (DA) system of the ventral midbrain plays a critical role as mammals learn adaptive behaviors driven by environmental salience and reward. Addictive drugs, including nicotine, exert powerful influences over the mesolimbic DA system by activating and desensitizing nicotinic acetylcholine receptors (nAChRs) in a subtype-dependent manner. Nicotine induces synaptic plasticity at excitatory synapses onto DA neurons, thereby sending elevated DA signals that participate during the reinforcement of addictive behaviors. While humans and animals of any developmental age are potentially vulnerable to these drug-induced effects, evidence from clinical and epidemiological studies indicates that adolescents have an increased risk of addiction. Although this risk arises from a complex set of variables including societal and psychosocial influences, a contributing factor involves age-dependent sensitivity to addictive drugs. One aspect of that sensitivity is drug-induced synaptic plasticity at excitatory synapses onto the dopamine neurons in the ventral midbrain. A single, acute exposure to addictive drugs, including nicotine, produces long term potentiation (LTP) that can be quantified by measuring the shift in the subtypes of ionotropic glutamate receptors mediating evoked synaptic transmission. This change in glutamatergic

© 2009 Elsevier Inc. All rights reserved.

Please address correspondence to: Dr. John A. Dani, Department of Neuroscience, Baylor College of Medicine, Houston, Texas, 77030, jdani@cns.bcm.edu, Telephone: 713-798-3710, Fax: 713-798-3946.

Classification: Special Issue for "Nicotinic Receptors-Based Therapeutics"

The authors declare that they have no competing financial interests.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

transmission is expressed as an increased ratio of AMPA receptors to NMDA receptors at glutamatergic synapses. Age-related differences in the excitability and the nicotine sensitivity within the midbrain dopamine system may contribute to the greater risk of nicotine addiction in adolescent animals and humans.

Keywords

Nicotinic Acetylcholine Receptors; Mesolimbic; Long-term Potentiation; Development; Ventral Tegmental Area; Nicotine Addiction

1. Introduction

Nicotine is the primary addictive substance in tobacco smoke [1-6], yet many important questions remain regarding its effects on the brain. Nicotine produces a variety of complex effects on several brain regions that are essential for the manifestation of addictive behavior [6-8]. The mesolimbic DA system is a target for addictive drugs that includes the DA neurons of the ventral tegmental area (VTA) projecting to the nucleus accumbens (NAc) of the ventral striatum [9-12]. A single dose of nicotine induces synaptic plasticity that increases the activity of VTA DA neurons [9,11,13,14]. This plasticity is similar in nature to activity-induced LTP [15,16], and is correlated in animal studies with psychostimulant-induced behavioral sensitization [17] and drug self-administration [18].

Tobacco use, primarily in the form of cigarette smoking, is a behavior that frequently occurs during adolescence. In the United States most smokers begin using before the age of 18 [19-21], and these young people are more likely to make the transition to a daily smoking habit [22-25]. Although several studies using rodent models have examined the effects of addictive drugs during adolescence, relatively little is known about developmental factors affecting the synaptic changes induced by nicotine in the VTA. Here we will describe nicotinic synaptic mechanisms of the mesolimbic DA system, and will describe age-dependent differences in the vulnerability to nicotine addiction in animal studies.

2. The role of midbrain dopamine neurons in nicotine addiction

2.1 The mesolimbic dopamine system

The cellular and molecular processes that are targeted by addictive drugs normally reinforce successful behaviors arising from interaction with a changing environment. Our understanding of the nature of DA signaling has evolved from that of a mediator of the experience of reward, to a reinforcer of rewarding behavior [2,26,27]. The concentrations of DA in the nucleus accumbens (NAc) do not scale directly with reward, but rather the DA signal is associated with novelty or gives an indication of deviation of environmental stimuli from the organism's expectations. Thus, among its other roles, DA contributes to the associative learning of survival-related behaviors as an organism develops an internal representation of environmental saliency [27].

As the addiction process progresses, drugs act upon the dopaminergic systems to reinforce behaviors, which involves learning environmental cues leading to or associated with drug-taking [2,3,7,28-36]. Nicotine stimulates midbrain DA neurons by activating nAChRs [10, 14,30,37-42], and it stimulates the prolonged release of DA in the NAc [14,33,34,43]. In rodent studies, DA antagonists or critical lesions of the mesolimbic DA system reduce nicotine self-administration [2,29,44-46]. In addition to its effects on midbrain DA neurons, nicotine can also act upon the DA fibers and presynaptic targets to regulate DA signaling in striatal regions [47-49]. Beyond the cellular changes produced by acute drug exposure, chronically

administered addictive substances produce additional neural changes. Because those neural changes are not completely characterized, they are called “neuroadaptations”, referring to a new neural condition that is reached via homeostatic adjustments to the repeated presence of the drug [6,26,50]. An example is the upregulation of mainly high affinity nAChR subtypes in specific neural locations after chronic nicotine [51].

The behavioral phenomena of drug tolerance and dependence are, in part, explained by the cellular and molecular changes caused by the addictive drug. Neural plasticity of the kind that underlies learning and memory contributes to the long-term motivations and cravings that can persist long after an addict has ceased to self-administer a particular drug. In these cases, re-experiencing environmental cues linked to drug use increase the likelihood of future drug cravings and possibly relapse even after long periods of abstinence [2,6,7,26,28]. Equally important, these cues motivate continued drug use and the maintenance of the addiction. Through their ability to initiate and modulate normal synaptic plasticity mechanisms, addictive drugs induce associated learning and memory that is an inherent and essential component of the overall addiction process.

2.2 Effects of nicotine on midbrain nicotinic receptors

Nicotine activates neurons of the ventral midbrain [7,10,14,37-42,52], and increases DA release to targets including the NAc [14,33,34,43]. The act of smoking cigarettes delivers approximately 50 to 500 nM nicotine to the brain over the course of seconds to minutes [3, 53-55]. Afterwards low concentrations of nicotine persist in the brain for several hours.

Neuronal nAChRs are pentameric ligand-gated ion channels that can be assembled from a combination of subunits: $\alpha 2$ - $\alpha 10$ and $\beta 2$ - $\beta 4$. Thus, a large number of structurally and functionally different nAChR subtypes can result [41,56-60]. The majority of heteromeric neuronal nAChRs are produced by the combination of alpha subunits ($\alpha 2$ - $\alpha 6$) and beta subunits ($\beta 2$ - $\beta 4$). The other major neuronal nAChR subtype contains the $\alpha 7$ subunit ($\alpha 7^*$ nAChRs), which has rapid activation and desensitization kinetics, and is selectively blocked by α -bungarotoxin (α -BTX) or methyllycaconitine (MLA) [9,61,62]. While relatively high agonist concentrations will cause a rapid desensitization of $\alpha 7^*$ nAChRs, a low affinity for nicotine means that they are able to maintain a steady-state activation in the presence of low concentrations of nicotine, such as those delivered by cigarette smoke [14,41,63].

In addition to its action at DA neurons in the midbrain, nicotine also produces modulatory effects via nAChRs at axonal, perisynaptic, presynaptic, and non-synaptic locations. The DA neurons of the midbrain primarily express nAChRs with relatively slow kinetics and a sensitivity to inhibition by dihydro- β -erythroidine (DH β E) [10,40,41,64], indicating that the predominant nAChR subtype is composed of $\beta 2$ -containing ($\beta 2^*$) nAChRs. These $\beta 2$ subunits co-assemble with other nicotinic receptor subunits, specifically $\alpha 4$, $\alpha 6$, and $\alpha 3$ [64-69], a conclusion that is supported by studies using $\beta 2$ -subunit knockout mice in which midbrain DA neurons have significantly diminished nicotinic receptor-mediated currents [40,41]. Although the $\beta 2^*$ nAChRs compose the main nicotinic receptor subtype in midbrain DA neurons, the $\beta 2$ -null mice do show a relatively small, MLA-sensitive current with rapid kinetics, indicating a minor amount of $\alpha 7^*$ nAChR expression [41].

2.3 The influence of nicotine on midbrain synaptic function

Nicotine, at concentrations approximating those experienced by cigarette smokers, modulates excitatory afferent signaling to midbrain DA neurons. The best characterized effect arises from presynaptic nAChRs, as exemplified by nicotine increasing the frequency (but not the amplitude) of spontaneous excitatory postsynaptic currents (sEPSCs) [7,11,14,39,70]. This effect on sEPSC frequency persists during the entire 25-min nicotine delivery period, indicating

there is not profound desensitization of the presynaptic nAChRs on the glutamatergic afferents [14]. In addition to enhancing sEPSC, nicotine increases the amplitude of weakly evoked EPSCs onto DA neurons. The nicotine-induced increase in either spontaneous or weakly evoked excitatory currents persists even after nicotine is removed from the bath solution, suggesting the induction of long-term potentiation [7,11,14,39,70,71]. Similar presynaptic effects mediated by nAChRs have also been demonstrated in other important brain regions, including the hippocampus [7,9,57-59,71-78]. This type of long-lived enhancement of excitatory synaptic transmission onto DA neurons is similar in many respects to the synaptic plasticity that has been linked to learning and memory [79].

Direct nicotine excitation of DA neurons gradually decreases owing to desensitization of the predominant $\beta 2^*$ nAChR subtypes. However, concurrent nicotine-mediated modulation of afferent synaptic activity permits continued excitation, prolonging the microdialysis DA signal measured in the NAc [2,14,29,30,34,43,80-82]. In simplified summary, smoking a cigarette provides an initial dose of nicotine that activates postsynaptic $\beta 2^*$ nAChRs on DA neurons and presynaptic $\alpha 7^*$ nAChRs located on the excitatory glutamatergic terminals that project onto the DA neurons. The $\beta 2^*$ nAChRs significantly desensitize after the initial activation, but the $\alpha 7^*$ nAChR are not significantly desensitized by the nicotine concentration obtained from a cigarette [7,14,41]. Since $\alpha 7^*$ -type nAChRs are highly calcium permeable, they often have the combined effect of mediating a direct calcium influx in addition to causing calcium increases indirectly via voltage-gated calcium channels and via release from intracellular Ca^{2+} stores [7,9,11,39,58,70,71,76,77,83,84]. Thus, activation of presynaptic $\alpha 7^*$ nAChRs increases calcium in glutamatergic presynaptic terminals, facilitating glutamate release and subsequent synaptic excitation of DA neurons despite desensitization of the postsynaptic $\beta 2^*$ nAChRs on the DA neurons. After nicotine initially excites VTA DA neurons increasing their action potential firing rate, postsynaptic activity is coupled with a nicotine-induced increase in presynaptic glutamatergic afferent excitation. It is this combination of presynaptic and postsynaptic coincidence that facilitates the formation of LTP [7,11,14,39,70,71].

In contrast to the sustained enhancement of excitatory afferent transmission onto VTA DA neurons, nicotine has a qualitatively different effect on the inhibitory, GABAergic inputs. Nicotinic receptor activation at somatic or preterminal sites, is known to produce local membrane depolarization sufficient to cause or facilitate action potential firing. In this way, bath application of nicotine initially increases action potential firing in GABAergic neurons. However, because of the specific subtypes of nicotinic receptors expressed in these inhibitory neurons (primarily the $\beta 2^*$ subtype), sustained exposure to bath-applied nicotine causes nAChR desensitization [7,12,14]. This ultimately reduces local inhibitory tone and increases DA neuron excitability, which increases the likelihood of glutamatergic LTP. The synaptic changes that are brought about by nicotine are very similar to the normal kinds of synaptic plasticity that are thought to contribute to learning and memory. Nicotine influences these normally adaptive pathways, favoring potentiation of synaptic activity related to drug-associated behaviors that are ultimately detrimental to the organism.

3. Nicotine and the adolescent brain

3.1 Vulnerability to nicotine addiction in adolescent humans

More than 60% of young people in the U.S. have tried smoking, and of those, one-half to one-third will make the transition into a daily smoking habit [25]. Commonly those who become regular smoker have their cigarette consumption escalate over a couple of years, but the addiction process proceeds relatively quickly in adolescents [21,85]. About 25% of the adolescents who smoke report symptoms of addiction at the time they establish a monthly smoking habit [85,86]. Nicotine has been reported to have positive effects on mood and behavior, but the initial exposure to cigarette smoke is often perceived as aversive [87-89].

However, when compared to adults, adolescents report more positive effects and fewer aversive effects during their first smoking experience [85].

3.2 Studies in animal models

Accumulating evidence from studies using rodent models continues to show significant age-related differences that may contribute to adolescent vulnerability to nicotine addiction [90]. In studies using young rats, a single dose of nicotine is sufficient to cause meaningful synaptic and cellular changes [11,13,91]. Young rats are also more sensitive than adult rats to nicotine's ability to reinforce intravenous self-administration and place preference conditioning [92]. Nicotine exposure in adolescent rats can also affect how the animal responds to subsequent exposure during adulthood, as this has been shown to increase self-administration later in life [93]. Adolescent rats also show greater levels of immediate early gene induction in the NAc in response to nicotine [94,95].

In making comparisons between rodents and humans, it is important to note that the first 21 postnatal days for the rat or mouse are approximately equivalent to the third trimester of prenatal development in the human [96,97]. During this early postnatal period, the rodent brain is subject to a significant degree of developmentally regulated gene expression, including genes for nAChRs that play key roles in neuronal development [96,98]. The subsequent juvenile and periadolescent periods also display complex changes in nicotinic receptor gene expression in midbrain catecholaminergic neurons. Despite these changes, age-related functional differences between midbrain DA neurons in young and adult mice can be highly specific. As an example of this, a comparison of several basic properties related to neuronal excitability show that the midbrain DA neurons of young and adult C57/BL6 mice are similar under basal conditions (Table 1).

Despite their functional similarities, these same populations of DA neurons show significant differences in excitability when depolarized by direct current injection (Figure 1). The VTA DA neurons of young mice show a current-frequency relationship that is not statistically different from adult mice (Figure 1B), but they are capable of sustaining a larger number of action potentials when depolarized (Figure 1C). This suggests that the same level of excitation may have different effects on DA release in the target regions of these neurons.

Another example of a potentially important difference between young and adult VTA DA neurons is seen in their relative sensitivity to nicotine-induced LTP. Addictive drugs are capable of producing LTP in VTA DA neurons [13,15], and this LTP is correlated with addiction-related behaviors in rodents, including behavioral sensitization [17] and drug self-administration [18]. Acute systemic injections of nicotine produce a shift in the ratio of excitatory glutamate receptor subtypes indicating the induction of LTP [13]. This potentiation is measured experimentally as an increase in the AMPAR/NMDAR current ratio of evoked EPSCs and is consistent with an NMDAR-mediated mechanism [15,99].

While acute nicotine injections will increase the AMPAR/NMDAR ratio in both young and adult C57 mice, a lower dose of nicotine is required in young mice to produce the same magnitude of increase. As shown in Figure 2, a single injection (1 mg/kg, intraperitoneal) of nicotine given 24 hours prior induces an increase in the AMPAR/NMDAR ratio in both adult and young mice (Figure 2C). This result suggests LTP induction, and based on control experiments by others [13,15], this expectation is supported for nicotine. In C57 mice, intraperitoneal injection of nicotine at 1 mg/kg corresponds to a peak plasma concentration of approximately 100 ng/ml, with the peak occurring about 5 minutes post-injection. However, the rapid metabolism of nicotine by mice results in a brief half-life of 6-7 minutes [100]. The peak nicotine concentration in this case is higher than has been estimated in humans after cigarette smoking (10-50 ng/ml, [101]).

At a lower concentration of nicotine (0.4 mg/kg), a difference is seen between adult and young mice. When we administered nicotine (0.4 mg/kg, i.p.), there was a significantly greater increase in the AMPAR/NMDAR ratio in the young mice: compare Figure 2A to Figure 2B with the results summarized in Figure 2C. This result suggests that the developing brain may be more sensitive to nicotine-induced long-term potentiation, and gives rise to the speculation that this sensitivity may contribute to a greater likelihood of nicotine-induced DA signals that contribute to addiction during adolescence.

With in vivo systemic delivery, nicotine will bind to its target receptors in a wide variety of brain regions, including those in the midbrain. While there are multiple nAChR subtypes that are activated and desensitized by nicotine, the particular subtypes that have been shown to be significant for the activation of the VTA dopaminergic system include the $\alpha 4\beta 2^*$ and the $\alpha 7^*$ subtypes. Studies in mice using radiolabeled nicotine and the $\alpha 7$ selective antagonist α -bungarotoxin have suggested that general patterns of expression resemble the adult brain by 20 days after birth [102]. Also, midbrain mRNA levels for $\alpha 4\beta 2$ and $\alpha 7$ have similarly been reported to be relatively unchanged from adolescence to adulthood in rats [98,103]; but see [104]. However, important brain regions with excitatory projections to the VTA, such as prefrontal cortex, show elevated nAChR expression during adolescence [96], which could contribute to the differences shown in Figure 2. Furthermore, evidence from rat studies shows increased mRNA levels of the $\alpha 6$ nAChR subunit within the VTA during adolescence [98]. This finding may be particularly relevant in light of the evidence for $\alpha 6$ containing receptors regulating VTA DA neuron firing [105], and nicotine self-administration [106].

Taken together, the literature and current data suggest that adolescent humans have an increased likelihood of attaining smoking behavior and an increased susceptibility of becoming addicted. Animal experiments support the epidemiology studies in humans by showing nicotine to have significant age-related effects on synaptic events and behavioral output. In vitro studies also indicate mechanistic differences between young and adult animals in their excitability and in their sensitivity to nicotine-induced synaptic plasticity.

4. Therapeutic implications

The most obvious practical application of the findings described here is to increase efforts to prevent young people from using tobacco. The overall evidence indicates that there is a greater risk of developing a lifelong addiction when nicotine is used during adolescence. Prevention strategies are primarily the domain of policy makers and educators, but there are also intriguing implications for pharmacotherapy. There are some specific examples of drugs that illustrate how developmental factors can have dramatic effects on the nature of drug therapy. Perhaps the most well known example comes from the clinical use of the stimulant methylphenidate, which reduces the signs and symptoms of attention-deficit hyperactivity disorder (ADHD) in children [107]. Like other stimulant treatments for ADHD, methylphenidate has a paradoxical effect in that it can have calming effects on children, while having the opposite effect on adults.

In the case of developmental factors contributing to nicotine dependence, the first and best approach to the problem is one of prevention, especially in the case of children and adolescents. However, as we gain a better understanding of the specific mechanistic differences between the developing brain and the adult brain, there is the potential for emerging strategies to exploit these differences. As better smoking cessation drugs are developed, this may come in the form of specific drug dosing regimens tailored to adolescents, or even specific compounds with superior efficacy in helping younger smokers to quit. Although some studies have begun to address adolescent issues [108,109], few clinical studies have focused specifically on adolescent responses during smoking cessation therapies. A recent prospective study of young smokers who started between the ages of 12 and 18 years indicated that 1 in 4 reported a desire

to quit smoking within a period of a few months, and that the first serious attempt to quit came an average of 2.5 months after the first cigarette [86]. Despite expressing a desire to quit, significant numbers of these smokers had difficulty doing so, underscoring a real need to develop effective approaches to assist this vulnerable population in quitting tobacco use. In light of this, any attempts to use specific drug therapies in adolescent populations will benefit from continued study of the underlying synaptic mechanisms that place the developing brain at greater risk of nicotine addiction.

Acknowledgments

This work was supported by grants from NINDS (R01NS021229) and NIDA (R01DA009411), and postdoctoral support from the Philip Morris Extramural Research Program and NIDA (F32DA024954).

Abbreviations

AMPA, α -amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
 α -BTX, α -bungarotoxin
 ACh, acetylcholine
 ADHD, attention-deficit hyperactivity disorder
 DH β E, dihydro- β -erythroidine
 DA, dopamine
 sEPSCs, spontaneous excitatory postsynaptic currents
 LTP, long term potentiation
 MLA, methyllycaconitine
 NMDA, N-methyl-D-aspartic acid
 nAChR, nicotinic acetylcholine receptor
 NAc, nucleus accumbens
 VTA, ventral tegmental area

References

- [1]. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. *Neuron* 1996;16:905–8. [PubMed: 8630247]
- [2]. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. *Eur J Pharmacol* 2000;393:295–314. [PubMed: 10771025]
- [3]. Karan, L.; Dani, JA.; Benowitz, N. The Pharmacology of Nicotine and Tobacco. In: Graham, AW.; Schultz, TK.; Mayo-Smith, MF.; Ries, RK.; Wilford, BB., editors. *Principles of Addiction Medicine*. American Society of Addiction Medicine; Chevy Chase, MD: 2003. p. 225–48.
- [4]. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus. *Nicotine Tob Res* 2004;6:899–912. [PubMed: 15801566]
- [5]. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. *Neuropharmacology* 2004;47(Suppl 1):227–41. [PubMed: 15464140]
- [6]. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. *Nat Neurosci* 2005;8:1465–70. [PubMed: 16251989]
- [7]. Dani JA, Ji D, Zhou FM. Synaptic plasticity and nicotine addiction. *Neuron* 2001;31:349–52. [PubMed: 11516393]
- [8]. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. *Annu Rev Neurosci* 2006;29:565–98. [PubMed: 16776597]
- [9]. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. *Nature* 1996;383:713–6. [PubMed: 8878480]
- [10]. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. *Nature* 1997;390:401–4. [PubMed: 9389479]

- [11]. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. *Neuron* 2000;27:349–57. [PubMed: 10985354]
- [12]. Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. *Neuron* 2002;33:905–19. [PubMed: 11906697]
- [13]. Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. *Neuron* 2003;37:577–82. [PubMed: 12597856]
- [14]. Pidoplichko VI, Noguchi J, Areola OO, Liang Y, Peterson J, Zhang T, et al. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. *Learn Mem* 2004;11:60–9. [PubMed: 14747518]
- [15]. Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. *Nature* 2001;411:583–7. [PubMed: 11385572]
- [16]. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. *Annu Rev Neurosci* 2002;25:103–26. [PubMed: 12052905]
- [17]. Borgland SL, Malenka RC, Bonci A. Acute and chronic cocaine-induced potentiation of synaptic strength in the ventral tegmental area: electrophysiological and behavioral correlates in individual rats. *J Neurosci* 2004;24:7482–90. [PubMed: 15329395]
- [18]. Chen BT, Bowers MS, Martin M, Hopf FW, Guillory AM, Carelli RM, et al. Cocaine but not natural reward self-administration nor passive cocaine infusion produces persistent LTP in the VTA. *Neuron* 2008;59:288–97. [PubMed: 18667156]
- [19]. WHO. Tobacco or health, a global status report. World Health Organization; 1997. p. 495
- [20]. Chen J, Millar WJ. Age of smoking initiation: implications for quitting. *Health Rep* 1998;9:39–46. 39–48. [PubMed: 9836879]EngFre
- [21]. Benowitz NL. Nicotine addiction. *Prim Care* 1999;26:611–31. [PubMed: 10436290]
- [22]. Taioli E, Wynder EL. Effect of the age at which smoking begins on frequency of smoking in adulthood. *N Engl J Med* 1991;325:968–9. [PubMed: 1881424]
- [23]. Breslau N, Peterson EL. Smoking cessation in young adults: age at initiation of cigarette smoking and other suspected influences. *Am J Public Health* 1996;86:214–20. [PubMed: 8633738]
- [24]. Kandel DB, Chen K. Extent of smoking and nicotine dependence in the United States: 1991–1993. *Nicotine Tob Res* 2000;2:263–74. [PubMed: 11082827]
- [25]. Henningfield JE, Moolchan ET, Zeller M. Regulatory strategies to reduce tobacco addiction in youth. *Tob Control* 2003;12(Suppl 1):i14–24. [PubMed: 12773782]
- [26]. Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. *Neuron* 2000;25:515–32. [PubMed: 10774721]
- [27]. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. *Science* 1997;275:1593–9. [PubMed: 9054347]
- [28]. Balfour DJ, Wright AE, Benwell ME, Birrell CE. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. *Behav Brain Res* 2000;113:73–83. [PubMed: 10942034]
- [29]. Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. *Psychopharmacology (Berl)* 1992;107:285–9. [PubMed: 1615127]
- [30]. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. *Pharmacol Biochem Behav* 2001;70:439–46. [PubMed: 11796143]
- [31]. Dani JA, Montague PR. Disrupting addiction through the loss of drug-associated internal states. *Nat Neurosci* 2007;10:403–4. [PubMed: 17387327]
- [32]. Nestler EJ. Cellular responses to chronic treatment with drugs of abuse. *Crit Rev Neurobiol* 1993;7:23–39. [PubMed: 8385579]
- [33]. Nisell M, Nomikos GG, Svensson TH. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. *Pharmacol Toxicol* 1994;75:348–52. [PubMed: 7534921]
- [34]. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. *Nature* 1996;382:255–7. [PubMed: 8717040]

- [35]. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. *Trends Neurosci* 1999;22:521–7. [PubMed: 10529820]
- [36]. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. *Trends Pharmacol Sci* 1990;11:216–9. [PubMed: 2200178]
- [37]. Calabresi P, Lacey MG, North RA. Nicotinic excitation of rat ventral tegmental neurones in vitro studied by intracellular recording. *Br J Pharmacol* 1989;98:135–40. [PubMed: 2804543]
- [38]. Grenhoff J, Johnson SW. Sulfonylureas enhance GABAA synaptic potentials in rat midbrain dopamine neurones. *Acta Physiol Scand* 1996;156:147–8. [PubMed: 8868271]
- [39]. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. *J Neurobiol* 2002;53:606–17. [PubMed: 12436424]
- [40]. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. *Nature* 1998;391:173–7. [PubMed: 9428762]
- [41]. Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. *J Neurosci* 2003;23:3176–85. [PubMed: 12716925]
- [42]. Zhang T, Zhang L, Liang Y, Siapas AG, Zhou FM, Dani JA. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. *J Neurosci* 2009;29:4035–43. [PubMed: 19339599]
- [43]. Clarke PB. Nicotinic receptor blockade therapy and smoking cessation. *Br J Addict* 1991;86:501–5. [PubMed: 1859912]
- [44]. Corrigall WA. Nicotine self-administration in animals as a dependence model. *Nicotine Tob Res* 1999;1:11–20. [PubMed: 11072385]
- [45]. Corrigall WA, Coen KM. Nicotine maintains robust self-administration in rats on a limited-access schedule. *Psychopharmacology (Berl)* 1989;99:473–8. [PubMed: 2594913]
- [46]. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. *Brain Res* 1994;653:278–84. [PubMed: 7982062]
- [47]. Jones IW, Bolam JP, Wonnacott S. Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones. *The Journal of comparative neurology* 2001;439:235–47. [PubMed: 11596051]
- [48]. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. *Eur J Pharmacol* 2000;393:51–8. [PubMed: 10770997]
- [49]. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. *Nat Neurosci* 2001;4:1224–9. [PubMed: 11713470]
- [50]. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. *Nicotine Tob Res* 2000;2:19–37. [PubMed: 11072438]
- [51]. Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. *J Neurosci* 2001;21:1819–29. [PubMed: 11245666]
- [52]. Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A. Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. *J Neurosci* 1985;5:1307–15. [PubMed: 3998824]
- [53]. Benowitz NL, Porchet H, Jacob P 3rd. Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. *Prog Brain Res* 1989;79:279–87. [PubMed: 2587748]
- [54]. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. *J Am Coll Cardiol* 1997;29:1422–31. [PubMed: 9180099]
- [55]. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. *Drug Alcohol Depend* 1993;33:23–9. [PubMed: 8370337]
- [56]. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu Rev Pharmacol Toxicol* 2007;47:699–729. [PubMed: 17009926]
- [57]. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. *Trends Neurosci* 1999;22:555–61. [PubMed: 10542436]

- [58]. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. *Annu Rev Physiol* 1995;57:521–46. [PubMed: 7778876]
- [59]. Role LW, Berg DK. Nicotinic receptors in the development and modulation of CNS synapses. *Neuron* 1996;16:1077–85. [PubMed: 8663984]
- [60]. Wonnacott S. Presynaptic nicotinic ACh receptors. *Trends Neurosci* 1997;20:92–8. [PubMed: 9023878]
- [61]. Alkondon M, Pereira EF, Wonnacott S, Albuquerque EX. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. *Mol Pharmacol* 1992;41:802–8. [PubMed: 1569927]
- [62]. Castro NG, Albuquerque EX. α -Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. *Biophys J* 1995;68:516–24. [PubMed: 7696505]
- [63]. Quick MW, Lester RA. Desensitization of neuronal nicotinic receptors. *J Neurobiol* 2002;53:457–78. [PubMed: 12436413]
- [64]. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. *J Neurosci* 2001;21:1452–63. [PubMed: 11222635]
- [65]. Charpentier E, Barneoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. *Neuroreport* 1998;9:3097–101. [PubMed: 9804323]
- [66]. Goldner FM, Dineley KT, Patrick JW. Immunohistochemical localization of the nicotinic acetylcholine receptor subunit $\alpha 6$ to dopaminergic neurons in the substantia nigra and ventral tegmental area. *Neuroreport* 1997;8:2739–42. [PubMed: 9295110]
- [67]. Le Novère N, Zoli M, Changeux JP. Neuronal nicotinic receptor $\alpha 6$ subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. *Eur J Neurosci* 1996;8:2428–39. [PubMed: 8950106]
- [68]. Wada E, McKinnon D, Heinemann S, Patrick J, Swanson LW. The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family ($\alpha 5$) in the rat central nervous system. *Brain Res* 1990;526:45–53. [PubMed: 2078817]
- [69]. Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, et al. Distribution of $\alpha 2$, $\alpha 3$, $\alpha 4$, and $\beta 2$ neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. *The Journal of comparative neurology* 1989;284:314–35. [PubMed: 2754038]
- [70]. Mansvelder HD, Lodder JC, Sons MS, Kits KS. Dopamine modulates exocytosis independent of $\text{Ca}(2+)$ entry in melanotropic cells. *J Neurophysiol* 2002;87:793–801. [PubMed: 11826047]
- [71]. Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. *Neuron* 2001;31:131–41. [PubMed: 11498056]
- [72]. Albuquerque EX, Pereira EF, Alkondon M, Schrattenholz A, Maelicke A. Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. *J Recept Signal Transduct Res* 1997;17:243–66. [PubMed: 9029494]
- [73]. Ge S, Dani JA. Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. *J Neurosci* 2005;25:6084–91. [PubMed: 15987938]
- [74]. Guo JZ, Tredway TL, Chiappinelli VA. Glutamate and GABA release are enhanced by different subtypes of presynaptic nicotinic receptors in the lateral geniculate nucleus. *J Neurosci* 1998;18:1963–9. [PubMed: 9482782]
- [75]. Li X, Rainnie DG, McCarley RW, Greene RW. Presynaptic nicotinic receptors facilitate monoaminergic transmission. *J Neurosci* 1998;18:1904–12. [PubMed: 9465015]
- [76]. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. *Science* 1995;269:1692–6. [PubMed: 7569895]
- [77]. Radcliffe KA, Dani JA. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. *J Neurosci* 1998;18:7075–83. [PubMed: 9736631]
- [78]. Radcliffe KA, Fisher JL, Gray R, Dani JA. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. *Ann N Y Acad Sci* 1999;868:591–610. [PubMed: 10414340]

- [79]. Martin SJ, Grimwood PD, Morris RG. Synaptic plasticity and memory: an evaluation of the hypothesis. *Annu Rev Neurosci* 2000;23:649–711. [PubMed: 10845078]
- [80]. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. *Eur J Pharmacol* 1999;375:13–30. [PubMed: 10443561]
- [81]. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci U S A* 1988;85:5274–8. [PubMed: 2899326]
- [82]. Imperato A, Mulas A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. *Eur J Pharmacol* 1986;132:337–8. [PubMed: 3816984]
- [83]. Rathouz MM, Vijayaraghavan S, Berg DK. Elevation of intracellular calcium levels in neurons by nicotinic acetylcholine receptors. *Mol Neurobiol* 1996;12:117–31. [PubMed: 8818146]
- [84]. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. Molecular cloning, functional properties, and distribution of rat brain $\alpha 7$: a nicotinic cation channel highly permeable to calcium. *J Neurosci* 1993;13:596–604. [PubMed: 7678857]
- [85]. DiFranza JR, Rigotti NA, McNeill AD, Ockene JK, Savageau JA, St Cyr D, et al. Initial symptoms of nicotine dependence in adolescents. *Tob Control* 2000;9:313–9. [PubMed: 10982576]
- [86]. O’Loughlin J, Gervais A, Dugas E, Meshefedjian G. Milestones in the process of cessation among novice adolescent smokers. *Am J Public Health* 2009;99:499–504. [PubMed: 18633080]
- [87]. Laviolette SR, van der Kooy D. The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the $\alpha 7$ -subunit-containing nicotinic acetylcholine receptor. *Psychopharmacology (Berl)* 2003;166:306–13. [PubMed: 12569428]
- [88]. Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. *Nature reviews* 2004;5:55–65.
- [89]. Wonnacott S, Sidhura N, Balfour DJ. Nicotine: from molecular mechanisms to behaviour. *Curr Opin Pharmacol* 2005;5:53–9. [PubMed: 15661626]
- [90]. Slotkin TA. Nicotine and the adolescent brain: insights from an animal model. *Neurotoxicol Teratol* 2002;24:369–84. [PubMed: 12009492]
- [91]. Jones S, Bonci A. Synaptic plasticity and drug addiction. *Curr Opin Pharmacol* 2005;5:20–5. [PubMed: 15661621]
- [92]. Levin ED, Rezvani AH, Montoya D, Rose JE, Swartzwelder HS. Adolescent-onset nicotine self-administration modeled in female rats. *Psychopharmacology (Berl)* 2003;169:141–9. [PubMed: 12764575]
- [93]. Adriani W, Spijker S, Deroche-Gamonet V, Laviola G, Le Moal M, Smit AB, et al. Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats. *J Neurosci* 2003;23:4712–6. [PubMed: 12805310]
- [94]. Schochet TL, Kelley AE, Landry CF. Differential expression of arc mRNA and other plasticity-related genes induced by nicotine in adolescent rat forebrain. *Neuroscience* 2005;135:285–97. [PubMed: 16084664]
- [95]. Shram MJ, Funk D, Li Z, Le AD. Acute nicotine enhances c-fos mRNA expression differentially in reward-related substrates of adolescent and adult rat brain. *Neurosci Lett* 2007;418:286–91. [PubMed: 17420096]
- [96]. Dwyer JB, McQuown SC, Leslie FM. The dynamic effects of nicotine on the developing brain. *Pharmacol Ther.* 2009
- [97]. Spear LP. Adolescent brain development and animal models. *Ann N Y Acad Sci* 2004;1021:23–6. [PubMed: 15251870]
- [98]. Azam L, Chen Y, Leslie FM. Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons. *Neuroscience* 2007;144:1347–60. [PubMed: 17197101]
- [99]. Kauer JA, Malenka RC. Synaptic plasticity and addiction. *Nature reviews* 2007;8:844–58.
- [100]. Petersen DR, Norris KJ, Thompson JA. A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. *Drug Metab Dispos* 1984;12:725–31. [PubMed: 6150822]

- [101]. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, et al. Guidelines on nicotine dose selection for in vivo research. *Psychopharmacology (Berl)* 2007;190:269–319. [PubMed: 16896961]
- [102]. Fiedler EP, Marks MJ, Collins AC. Postnatal development of two nicotinic cholinergic receptors in seven mouse brain regions. *Int J Dev Neurosci* 1990;8:533–40. [PubMed: 2281814]
- [103]. Zhang X, Liu C, Miao H, Gong ZH, Nordberg A. Postnatal changes of nicotinic acetylcholine receptor alpha 2, alpha 3, alpha 4, alpha 7 and beta 2 subunits genes expression in rat brain. *Int J Dev Neurosci* 1998;16:507–18. [PubMed: 9881299]
- [104]. Doura MB, Gold AB, Keller AB, Perry DC. Adult and periadolescent rats differ in expression of nicotinic cholinergic receptor subtypes and in the response of these subtypes to chronic nicotine exposure. *Brain Res* 2008;1215:40–52. [PubMed: 18474362]
- [105]. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, et al. In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. *Neuron* 2008;60:123–36. [PubMed: 18940593]
- [106]. Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, et al. Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. *J Neurosci* 2008;28:12318–27. [PubMed: 19020025]
- [107]. Connor DF. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. *J Dev Behav Pediatr* 2002;23:S1–9. [PubMed: 11875284]
- [108]. Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. *J Consult Clin Psychol* 2004;72:729–35. [PubMed: 15301658]
- [109]. Niederhofer H, Huber M. Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results. *Pharmacotherapy* 2004;24:1524–8. [PubMed: 15537557]

Figure 1.

VTA dopamine neurons from young mice are able to fire more action potentials than adult mice when depolarized as shown. A) Representative data showing a 200 pA/2s depolarization in either a young or adult mouse VTA DA neuron. B) Averaged data show that both groups fire at similar instantaneous frequencies when initially depolarized. C) The DA neurons from younger mice are able to fire more action potentials than those of older mice when depolarized by the indicated current injections (* $p < 0.05$, ** $p < 0.01$ by repeated measures ANOVA and Tukey's HSD *post hoc*, $n = 10-17$ per group).

Figure 2.

VTA DA neurons in young mice are more sensitive to nicotine-induced LTP. A) Representative averaged traces from young (p21-p35) and B) adult (p60-p90) mice after injection of 0.4 mg/kg nicotine ~24 hours prior to recording. The traces are averaged (12-15 sweeps) evoked currents from mouse midbrain DA neurons voltage-clamped at +40 mV in the presence of 100 mM picrotoxin to block GABA_A-mediated currents. Black traces indicate the remaining AMPAR component after a 5 min perfusion with 100 mM DL-AP5. Gray traces show a digital subtraction of the AMPAR-mediated currents from the total EPSCs, representing the NMDAR component. The larger AMPA/NMDA ratio is indicative of LTP induction. Scale bars indicate 100pA/10ms for the adult and 45pA/10ms for the juvenile. C) Averaged peak amplitude ratios obtained from either young or adult mice 24-48 h after i.p. injection with the indicated dose of nicotine showing a leftward shift in the dose-response relationship for young mice (* $p < 0.05$, young vs. adult at 0.4 mg/kg nicotine by repeated measures ANOVA and Tukey's HSD *post hoc*, $n=10-17$ per group, $n=5-7$ per group).

Table 1
Similar electrophysiological properties of VTA DA neurons in young and adult mice. Values represent mean $\pm$ s.e.m. No statistically significant differences were seen between young and adult C57BL/6 mice for each of the properties shown above

	Firing Frequency (Hz)	Resting Membrane Potential (mV)	Action Potential Width (ms)	I _h Amplitude (pA)	Input Resistance (mΩ)
Young (p21-p35) <i>n</i> = 17	1.9 $\pm$ 0.2	- 48.7 $\pm$ 0.7	2.2 $\pm$ 0.1	-263.6 $\pm$ 37.7	245.0 $\pm$ 17.9
Adult (p60-p90) <i>n</i> = 10	1.7 $\pm$ 0.4	- 46.1 $\pm$ 1.5	2.2 $\pm$ 0.1	-302.6 $\pm$ 39.0	204.1 $\pm$ 27.8